EPO attenuates inflammatory cytokines by Muller cells in diabetic retinopathy

Frontiers in Bioscience - Elite

Volumn 3 E, Issue 1, 2011, Pages 201-211

  Lei, Xia ^a,b,c   Zhang, Jingfa ^b   Shen, Jianfeng ^a,c   Hu, Liu Mei ^d   Wu, Yalan ^a   Mou, Lisha ^a,c   Xu, Guoxu ^e   Li, Weiye ^b,d,f   Xu, Guo Tong ^a,b  

^a Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

^b TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^c UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^d PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^e THE SECOND AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^f DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Activator Protein 1; Diabetic Retinopathy; Erythropoietin; IL 1beta; Inflammatory Cytokines; Muller Cells; TNF alpha

Indexed keywords

GLYOXAL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; RECOMBINANT ERYTHROPOIETIN; STREPTOZOCIN; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; CYTOKINE; ERYTHROPOIETIN; LUCIFERASE; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIAZOLYL BLUE; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENUATION; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DIABETIC RETINOPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INFLAMMATION; MALE; MUELLER CELL; NICK END LABELING; NONHUMAN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; REAL TIME POLYMERASE CHAIN REACTION; RNA PURIFICATION; STREPTOZOCIN DIABETES; TARGET CELL; ANIMAL; CELL LINE; EXPERIMENTAL DIABETES MELLITUS; GENE EXPRESSION REGULATION; IMMUNOLOGY; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

RATTUS;

ANIMALS; CELL LINE; CYTOKINES; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; ERYTHROPOIETIN; GENE EXPRESSION REGULATION; IN SITU NICK-END LABELING; INTERLEUKIN-1BETA; INTERLEUKIN-6; LUCIFERASES; NF-KAPPA B; RATS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TETRAZOLIUM SALTS; THIAZOLES; TRANSCRIPTION FACTOR AP-1; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79952666872     PISSN: 19450494     EISSN: 19450508     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. D. S. Fong, L. P. Aiello, F. L. Ferris, 3rd and R. Klein: Diabetic retinopathy. Diabetes Care 27, 2540-53 (2004) (Pubitemid 39281419)
2. J. L. Wautier and P. J. Guillausseau: Advanced glycation end products, their receptors and diabetic angiopathy. Diabetes Metab 27, 535-42 (2001) (Pubitemid 33051702)
3. J. Shen, Y. Wu, J. Y. Xu, J. Zhang, S. H. Sinclair, M. Yanoff, G. Xu, W. Li and G. T. Xu: ERK- and Aktdependent neuroprotection by erythropoietin (EPO) against glyoxal-AGEs via modulation of Bcl-xL, Bax, and BAD. Invest Ophthalmol Vis Sci 51, 35-46 (2009)
4. E. M. Kniep, C. Roehlecke, N. Ozkucur, A. Steinberg, F. Reber, L. Knels and R. H. Funk: Inhibition of apoptosis and reduction of intracellular pH decrease in retinal neural cell cultures by a blocker of carbonic anhydrase. Invest Ophthalmol Vis Sci 47, 1185-92 (2006) (Pubitemid 46768355)
5. H. Yamawaki and Y. Hara: Glyoxal causes inflammatory injury in human vascular endothelial cells. Biochem Biophys Res Commun 369, 1155-9 (2008)
6. A. M. Joussen, V. Poulaki, N. Mitsiades, B. Kirchhof, K. Koizumi, S. Dohmen and A. P. Adamis: Nonsteroidal antiinflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. Faseb J 16, 438-40 (2002)
7. A. Carmo, J. G. Cunha-Vaz, A. P. Carvalho and M. C. Lopes: Effect of cyclosporin-A on the blood - retinal barrier permeability in streptozotocin-induced diabetes. Mediators Inflamm 9, 243-8 (2000) (Pubitemid 32055503)
8. H. Funatsu, H. Yamashita, E. Shimizu, R. Kojima and S. Hori: Relationship between vascular endothelial growth factor and interleukin-6 in diabetic retinopathy. Retina 21, 469-77 (2001) (Pubitemid 32971356)
9. T. Qaum, Q. Xu, A. M. Joussen, M. W. Clemens, W. Qin, K. Miyamoto, H. Hassessian, S. J. Wiegand, J. Rudge, G. D. Yancopoulos and A. P. Adamis: VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci 42, 2408-13 (2001) (Pubitemid 32848873)
10. R. J. Walker and J. J. Steinle: Role of beta-adrenergic receptors in inflammatory marker expression in Muller cells. Invest Ophthalmol Vis Sci 48, 5276-81 (2007) (Pubitemid 351260941)
11. M. D. Shelton, T. S. Kern and J. J. Mieyal: Glutaredoxin regulates nuclear factor kappa-B and intercellular adhesion molecule in Muller cells: model of diabetic retinopathy. J Biol Chem 282, 12467-74 (2007) (Pubitemid 47100623)
12. Y. Xiong, D. Lu, C. Qu, A. Goussev, T. Schallert, A. Mahmood and M. Chopp: Effects of erythropoietin on reducing brain damage and improving functional outcome after traumatic brain injury in mice. J Neurosurg 109, 510- 21 (2008)
13. P. Villa, P. Bigini, T. Mennini, D. Agnello, T. Laragione, A. Cagnotto, B. Viviani, M. Marinovich, A. Cerami, T. R. Coleman, M. Brines and P. Ghezzi: Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J Exp Med 198, 971-5 (2003) (Pubitemid 37152934)
14. M. L. Brines, P. Ghezzi, S. Keenan, D. Agnello, N. C. de Lanerolle, C. Cerami, L. M. Itri and A. Cerami: Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci U S A 97, 10526-31 (2000)
15. M. Celik, N. Gokmen, S. Erbayraktar, M. Akhisaroglu, S. Konakc, C. Ulukus, S. Genc, K. Genc, E. Sagiroglu, A. Cerami and M. Brines: Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. Proc Natl Acad Sci U S A 99, 2258-63 (2002) (Pubitemid 34169048)
16. D. Agnello, P. Bigini, P. Villa, T. Mennini, A. Cerami, M. L. Brines and P. Ghezzi: Erythropoietin exerts an antiinflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis. Brain Res 952, 128-34 (2002) (Pubitemid 35279495)
17. A. Gorio, N. Gokmen, S. Erbayraktar, O. Yilmaz, L. Madaschi, C. Cichetti, A. M. Di Giulio, E. Vardar, A. Cerami and M. Brines: Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma. Proc Natl Acad Sci U S A 99, 9450-5 (2002) (Pubitemid 34764634)
18. C. Savino, R. Pedotti, F. Baggi, F. Ubiali, B. Gallo, S. Nava, P. Bigini, S. Barbera, E. Fumagalli, T. Mennini, A. Vezzani, M. Rizzi, T. Coleman, A. Cerami, M. Brines, P. Ghezzi and R. Bianchi: Delayed administration of erythropoietin and its non-erythropoietic derivatives ameliorates chronic murine autoimmune encephalomyelitis. J Neuroimmunol 172, 27-37 (2006) (Pubitemid 43279681)
19. J. Zhang, Y. Wu, Y. Jin, F. Ji, S. H. Sinclair, Y. Luo, G. Xu, L. Lu, W. Dai, M. Yanoff, W. Li and G. T. Xu: Intravitreal injection of erythropoietin protects both retinal vascular and neuronal cells in early diabetes. Invest Ophthalmol Vis Sci 49, 732-42 (2008)
20. W. Li, S. H. Sinclair and G. T. Xu: Effects of Intravitreal Erythropoietin Therapy for Patients with Chronic and Progressive Diabetic Macular Edema. Ophthalmic Surgery, Lasers and Imaging 41, 18-25 (2010)
21. T. S. Kern: Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp Diabetes Res 2007, 95103 (2007)
22. X. Liu, W. Xie, P. Liu, M. Duan, Z. Jia, W. Li and J. Xu: Mechanism of the cardioprotection of rhEPO pretreatment on suppressing the inflammatory response in ischemia-reperfusion. Life Sci 78, 2255-64 (2006)
23. N. Yazihan, O. Karakurt and H. Ataoglu: Erythropoietin reduces lipopolysaccharide-induced cell Damage and midkine secretion in U937 human histiocytic lymphoma cells. Adv Ther 25, 502-14 (2008)
24. C. Qin, Y. B. Xiao, Q. J. Zhong, L. Chen and X. F. Wang: Anti-inflammatory effect of erythropoietin pretreatment on cardiomyocytes with hypoxia/reoxygenation injury and the possible mechanism. Chin J Traumatol 11, 352-8 (2008)
25. W. M. Campana, X. Li, V. I. Shubayev, M. Angert, K. Cai and R. R. Myers: Erythropoietin reduces Schwann cell TNF-alpha, Wallerian degeneration and pain-related behaviors after peripheral nerve injury. Eur J Neurosci 23, 617-26 (2006)
26. Z. Y. Wang, L. J. Shen, L. Tu, D. N. Hu, G. Y. Liu, Z. L. Zhou, Y. Lin, L. H. Chen and J. Qu: Erythropoietin protects retinal pigment epithelial cells from oxidative damage. Free Radic Biol Med 46, 1032-41 (2009)
27. Q. L. Fu, W. Wu, H. Wang, X. Li, V. W. Lee and K. F. So: Up-regulated endogenous erythropoietin/erythropoietin receptor system and exogenous erythropoietin rescue retinal ganglion cells after chronic ocular hypertension. Cell Mol Neurobiol 28, 317-29 (2008) (Pubitemid 351253068)
28. M. Brines and A. Cerami: Emerging biological roles for erythropoietin in the nervous system. Nat Rev Neurosci 6, 484-94 (2005) (Pubitemid 40769173)
29. S. F. Yan, R. Ramasamy, Y. Naka and A. M. Schmidt: Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Circ Res 93, 1159-69 (2003) (Pubitemid 37543056)
30. J. Berlanga, D. Cibrian, I. Guillen, F. Freyre, J. S. Alba, P. Lopez-Saura, N. Merino, A. Aldama, A. M. Quintela, M. E. Triana, J. F. Montequin, H. Ajamieh, D. Urquiza, N. Ahmed and P. J. Thornalley: Methylglyoxal administration induces diabetes-like microvascular changes and perturbs the healing process of cutaneous wounds. Clin Sci (Lond) 109, 83-95 (2005) (Pubitemid 40943037)
31. S. Di Loreto, V. Caracciolo, S. Colafarina, P. Sebastiani, A. Gasbarri and F. Amicarelli: Methylglyoxal induces oxidative stress-dependent cell injury and upregulation of interleukin-1beta and nerve growth factor in cultured hippocampal neuronal cells. Brain Res 1006, 157- 67 (2004) (Pubitemid 38393760)
32. S. Kuntz, S. Rudloff, J. Ehl, R. G. Bretzel and C. Kunz: Food derived carbonyl compounds affect basal and stimulated secretion of interleukin-6 and -8 in Caco-2 cells. Eur J Nutr 48, 499-503 (2009)
33. R. Inagi, T. Miyata, T. Yamamoto, D. Suzuki, K. Urakami, A. Saito, C. van Ypersele de Strihou and K. Kurokawa: Glucose degradation product methylglyoxal enhances the production of vascular endothelial growth factor in peritoneal cells: role in the functional and morphological alterations of peritoneal membranes in peritoneal dialysis. FEBS Lett 463, 260-4 (1999) (Pubitemid 30001930)
34. J. Y. Jeong, G. Hoxhaj, A. L. Socha, A. J. Sytkowski and L. Feldman: An erythropoietin autocrine/paracrine axis modulates the growth and survival of human prostate cancer cells. Mol Cancer Res 7, 1150-7 (2009)
35. S. M. Kumar, G. Acs, D. Fang, M. Herlyn, D. E. Elder and X. Xu: Functional erythropoietin autocrine loop in melanoma. Am J Pathol 166, 823-30 (2005) (Pubitemid 40315639)
36. G. Acs, M. Chen, X. Xu, P. Acs, A. Verma and C. J. Koch: Autocrine erythropoietin signaling inhibits hypoxiainduced apoptosis in human breast carcinoma cells. Cancer Lett 214, 243-51 (2004) (Pubitemid 39207986)
37. A. Nagai, E. Nakagawa, H. B. Choi, K. Hatori, S. Kobayashi and S. U. Kim: Erythropoietin and erythropoietin receptors in human CNS neurons, astrocytes, microglia, and oligodendrocytes grown in culture. J Neuropathol Exp Neurol 60, 386-92 (2001) (Pubitemid 32274054)
38. J. Zhang, L. M. Hu, G. Xu, Y. Wu, J. Shen, Y. Luo, Y. Zhong, S. H. Sinclair, M. Yanoff, W. Li and G. T. Xu: Anti-VEGF effects of intravitreal erythropoietin in early diabetic retinopathy. Front Biosci (2010, in press)
39. G. Chen, J. X. Shi, C. H. Hang, W. Xie, J. Liu and X. Liu: Inhibitory effect on cerebral inflammatory agents that accompany traumatic brain injury in a rat model: a potential neuroprotective mechanism of recombinant human erythropoietin (rhEPO). Neurosci Lett 425, 177-82 (2007) (Pubitemid 47418362)
40. A. L. Wang, Z. Li, M. Yuan, A. C. Yu, X. Zhu and M. O. Tso: Sinomenine inhibits activation of rat retinal microglia induced by advanced glycation end products. Int Immunopharmacol 7, 1552-8 (2007) (Pubitemid 47505344)
41. L. P. Yang, H. L. Sun, L. M. Wu, X. J. Guo, H. L. Dou, M. O. Tso, L. Zhao and S. M. Li: Baicalein reduces inflammatory process in a rodent model of diabetic retinopathy. Invest Ophthalmol Vis Sci 50, 2319-27 (2009)